Theralase Technologies (TLT) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026, decreased by 5% year-over-year to $296,927, with a net loss reduction of 14% to $2,093,926, primarily due to lower research and development spending.

• The company completed enrollment in its Phase II bladder cancer clinical study, with 95 patients treated and 82 completing the study.

• A collaborative agreement with Ferring Pharmaceuticals was established to expand the clinical program, including a new cohort combining Ruvidar® and Adstiladrin®.

Financial highlights

• Gross margin improved to 50% of revenue from 42% year-over-year, despite a revenue decline.

• Administrative expenses rose 1% to $1,003,798, while research and development expenses dropped 25% to $1,101,126.

• Cash position increased significantly to $5,260,832 as of June 30, 2026, with an additional $3,555,000 raised post-quarter.

Outlook and guidance

• Plans to submit a New Drug Submission to Health Canada and a New Drug Application to the FDA in 3Q2026, with marketing decisions expected in 2027.

• Pursuing commercialization and strategic partnerships for Ruvidar® globally.

• GLP toxicology studies for Rutherrin® expected to complete by 4Q2026, with adaptive clinical studies planned for 2027.